Search by category - Any -Regulated informationInside informationNon-regulated information Search by year - Any -202620252024202320222021202020192018201720162015 15 November 2017 Idylla™ Performance Data Presented by US Key Opinion Leaders at Association for Molecular Pathology 2017 Conference Non-regulated information 5 September 2017 Idylla™ Respiratory (IFV-RSV) Panel receives 510(k) clearance by US FDA First test cleared for use on the Idylla™ platform by US FDA Non-regulated information 31 August 2017 Strong performance data of proprietary MSI Biomarkers for the Idylla™ MSI Test to be published at ESMO Non-regulated information 12 July 2017 Biocartis’ Idylla™ Instrument and Idylla™ Console exempt from US FDA 510(k) notification requirements Non-regulated information 10 July 2017 Biocartis and A*STAR’s ETPL initiate development of breast cancer assay to guide therapy selection Non-regulated information 13 June 2017 Biocartis launches CE-marked IVD test for lung cancer Idylla™ EGFR Mutation Test is the only on market fully automated CE-IVD test detecting all relevant EGFR mutations according to international guidelines Non-regulated information 7 June 2017 MRC Technology and Biocartis initiate development of liquid biopsy test for breast cancer Partnership aimed at the development of molecular diagnostic assays on Biocartis’ fully automated Idylla™ platform Non-regulated information 23 May 2017 Biocartis launches CE-marked IVD NRAS test for colorectal cancer Non-regulated information 18 May 2017 Study demonstrating high performance of Idylla™ liquid biopsy RAS tests to be presented at ASCO Annual Meeting Non-regulated information 4 April 2017 Biocartis establishes US subsidiary and appoints US General Manager Non-regulated information Pagination First page « First Previous page ‹‹ … Page 4 Page 5 Page 6 Page 7 Page 8 Current page 9 Page 10 Page 11 Page 12 Next page ›› Last page Last »